Racetam (nootropic)

Phenylpiracetam

Phenylpiracetam, also called fonturacetam or carphedon, appears on the WADA 2026 list among non-specified stimulants prohibited in-competition; the app lists a half-life of 4 hours.1

Anecdotal evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Phenylpiracetam after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.

Drawn from the half-life in the app's model, ~4 h. The model's figures

Phenylpiracetam is a racetam, a compound related to piracetam, which the app files as a stimulating racetam sold under the name Phenotropil.1,2 Zvejniece and colleagues at the Latvian Institute of Organic Synthesis (Basic and Clinical Pharmacology and Toxicology, 2011) describe it as "clinically used in its racemic form as a nootropic drug that improves physical condition and cognition".2 Malykh and Sadaie (Drugs, 2010) list it in a subgroup of piracetam-like drugs "which have been used in humans and some of which are available as dietary supplements", and write that "Phenylpiracetam is more potent than piracetam and is used for a wider range of indications".3 The app's note gives the potency as 60 times that of piracetam; the review's PubMed record states the comparison only as "more potent than piracetam" and gives no multiple.3 The app grades the evidence for phenylpiracetam as anecdotal. The human reports identified are mostly Russian-language studies whose PubMed records hold no full text, so the sections below rest on those records and on one registry entry.

A 2024 review by Gromova and Torshin (Federal Research Center "Computer Science and Control", Moscow) states that phenylpiracetam is "a nootropic drug with additional pharmacological effects, including anxiolytic, antiasthenic, antidepressant, anti-inflammatory and anticonvulsant effects".4 Malykh and Sadaie add that "The modes of action of piracetam and most of its derivatives remain an enigma".3 The mechanism evidence cited below comes from mice and rats, not from people.2,5

In mice, Zvejniece and colleagues (2011) tested racemic phenotropil and its two enantiomers and reported that locomotor activity rose "after a single administration of R-phenotropil at doses of 10 and 50 mg/kg and S-phenotropil at a dose of 50 mg/kg".2 In the same mouse work, "R-phenotropil significantly enhanced memory function in a passive avoidance response test at a dose of 1 mg/kg; the S-enantiomer did not show any activity in this test", although brain concentrations of the two forms were similar.2 Its PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and gives no further funding statement.2 The same Latvian group wrote in 2017 that "it was shown that S-phenylpiracetam is a selective dopamine transporter (DAT) inhibitor that does not influence norepinephrine (NE) or serotonin (5-HT) receptors".5 In Western diet-fed mice and obese Zucker rats given S-phenylpiracetam by mouth for 8 and 12 weeks, "S-phenylpiracetam treatment significantly decreased body weight gain and fat mass increase", with no change in locomotor activity.5 One of the nine listed authors of that paper is affiliated with JSC Olainfarm, Olaine, Latvia; the PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and gives no further funding statement.5 A 2020 mouse study of R-phenylpiracetam reported that "DAT was the only significant molecular target found for R-PhP" in radioligand binding assays, and that a single intraperitoneal injection attenuated the lipopolysaccharide-induced fall in body temperature and the rise in inflammatory gene expression.6 No human study of these dopamine transporter or anti-inflammatory findings was identified in the searches described under "What is not known".

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
99%
Typical dose
100–200 mg/dose
Route
Oral
Time to peak
~1 h

Sources in this part

  1. 6Zvejniece et al., 2020

The app lists a half-life of about 4 hours, 99% bioavailability, a time to peak of about 1 hour and a duration of about 6 hours. The records give no human half-life, bioavailability or time to peak, so the table shows the app's figures without a source figure beside them.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~4 hNo human half-life identified in the sources read
Bioavailability99%No human bioavailability identified in the sources read
Time to peak~1 hNo human time to peak identified; in mice, R-phenylpiracetam at 50 mg/kg "reached the brain tissue 15 min after intraperitoneal (ip) and peroral (po) injections"6
Maximum brain concentration (mice)Not in the app28 µg/g tissue after intraperitoneal and 18 µg/g after peroral administration of R-phenylpiracetam at 50 mg/kg6
Duration of effect~6 hNo figure identified in the sources read

Because none of the sources reports a half-life interval for people, a level chart is not shown.

4

Human studies

Table 4.1Human studies4 rows
Study and yearDesignPeopleDose and lengthMain result
Fedin and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 20147Non-interventional observational program (TRIUMPH) in primary health care1170 patients with brain ischemia, aged 45-65 years100 mg, over 2 and 3 months"More than 2-fold decrease in the severity of asthenia symptoms was achieved in all subgroups 3 months after treatment"; adverse events not stated in the record
Devlikamova and Safina, Zh Nevrol Psikhiatr Im S S Korsakova 20258Systematic review and meta-analysis of 11 articles549 patients with asthenia (mean age 45.9 years)200 mg daily, one-month courseMFI-20 asthenia score reduced by an average of 16.3 points (95% CI 8.85-23.85) after a course, with no control comparator stated in the record; side effects averaged 5.5% and were described as transient
Medvedev and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 20149Controlled clinical trial against a comparison group35 patients on phenotropil and 35 in the comparison group, with cardiovascular disease and mild neurotic, somatoform, stress-induced or depressive disorders12 weeks; dose not stated in the recordEffect "in particular anxiolytic one" of phenotropil "decreased after 4-8 weeks of treatment", while the record reports statistically significant advantages of the other drug, pantogam active, on a number of values; "The tolerability of both drugs was satisfactory"
NCT07852130, registered 202610Randomised, placebo-controlled, parallel; described as partially blinded70 healthy adults aged 18-35, about nine on phenylpiracetam100, 200 or 300 mg/day by mouth, up to six monthsStatus completed; the entry's results field reads "Has Results: undefined"

Deeper analysis: the TRIUMPH observational program (Fedin, 2014)

Fedin and colleagues, from a Moscow medical university, reported an observational program in primary health care of patients with chronic brain ischemia, published in Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova in 2014.7 They measured asthenic syndrome with clinical examination and MFI-20 subscales in 1170 patients aged 45-65 years given phenotropil 100 mg for 2 and 3 months.7 The record reports that "The high incidence of asthenic syndrome was observed across all MFI-20 subscales" and that "The decrease in asthenic syndrome severity was significant already in the end of the first month of treatment with phenotropil".7 Severity fell more than 2-fold in all subgroups at 3 months, and "More rapid and apparent decrease in asthenic syndrome was observed in younger patients".7 The PubMed record describes a single treated group and does not mention a comparison group, adverse events, discontinuations, funding, author ties to a manufacturer or the authors' own limitations, so those cannot be reported here.

Deeper analysis: the fonturacetam meta-analysis (Devlikamova and Safina, 2025)

Devlikamova and Safina, of Kazan State Medical Academy and Kazan Federal University, pooled 11 articles on fonturacetam (listed by WADA as 4-phenylpiracetam, carphedon) in asthenia.8,1 The 549 patients all received 200 mg daily, and the MFI-20 score fell by an average of 16.3 points (95% CI 8.85-23.85) after a one-month course, assessed on day 30.8 The record also lists a "positive effect on emotional background, sleep, cognitive functions, quality of life" and reports that "Side effects were transient and completely regressed within a week of continued treatment".8 The authors conclude that "Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy".8 The PubMed record reports the change after a course and does not say whether the pooled change was measured against a control group; it gives no funding statement, no author ties to a manufacturer and no limitations section.8

Deeper analysis: the comparison trial in cardiovascular patients (Medvedev, 2014)

Medvedev and colleagues studied "the efficacy and tolerability of the drugs pantogam active and phenotropil" in patients with cardiovascular disease and mild neurotic, somatoform, stress-induced or depressive disorders.9 The record states that the 35 patients treated with phenotropil for 12 weeks were compared with a comparison group of 35, assessed with CGI, HDRS and adverse-effect scales.9 The authors report statistically significant advantages of the other drug, pantogam active, on a number of values, whose effect gradually increased, while "the effect (in particular anxiolytic one) of phenotropil decreased after 4-8 weeks of treatment", and that "The tolerability of both drugs was satisfactory"; the record says the effect of pantogam active was assessed in an open study.9 The record does not state the phenotropil dose, adverse event counts, funding or the authors' limitations, and its wording of the comparison group is unclear.9

Deeper analysis: registry entry NCT07852130

The ClinicalTrials.gov entry names Abdulraheem Mohamed Gouda of the Reserology Research Foundation as lead sponsor and investigator, and lists the study as completed with a status verified in September 2026.10 The design is a randomised, parallel study of 70 healthy adults aged 18-35 in which 25 received an inert matched preparation and 45 were spread across modafinil and four racetams, with phenylpiracetam at 100, 200 or 300 mg/day for six months.10 The registered primary outcome is response initiation latency, with standardized IQ test scores and sleep restriction as further conditions.10 The entry states its own limits: with about nine participants per compound it was "designed to detect only very large effects", the expectancy component "was not implemented", and the study is "described as placebo-controlled and partially blinded rather than double-blind".10 The entry gives no data on deaths, serious adverse events or discontinuations, and no results were posted in the record read.10 The entry's first submission date is 2026-09-15, after its recorded completion date of 2026-09-12, and its primary purpose is listed as basic science.10

5

Doses reported in studies and on labels

No US label for phenylpiracetam was identified: a DailyMed search returned 0 labels. The app's typical dose is 100–200 mg per dose, while the sources below give totals per day or per course, so the two are not on the same basis.

Table 5.1Doses reported in studies and on labels4 rows
SourceDose as reportedContext
Fedin and colleagues, 20147100 mg for 2 and 3 months1170 patients with brain ischemia aged 45-65 years; observational program
Devlikamova and Safina, 20258200 mg dailyMeta-analysis of 11 articles, 549 patients with asthenia; one-month course
NCT0785213010100, 200 or 300 mg/day by mouth70 healthy adults across all arms; six-month registered study with no posted results
Vanhee and colleagues, 202511100–200 mg/dayDescribed by the authors as the typical pharmacological dosage of a prescription medication available in Russia

Devlikamova and Safina report that in their meta-analysis of fonturacetam at 200 mg daily "the frequency of side effects averaged 5.5%", and that these "were transient and completely regressed within a week of continued treatment".8 Medvedev and colleagues write that "The tolerability of both drugs was satisfactory" in a 12-week comparison of 35 patients treated with phenotropil with a comparison group of 35.9 The Fedin record and the registry entry give no adverse event counts.7,10 The app's note says that tolerance builds fast and mentions racetam headaches; none of the records read reported on tolerance or headaches with phenylpiracetam. Cohen and colleagues, who tested supplements sold in the United States, write that the health effects of untested combinations of unapproved drugs at unpredictable dosages in supplements "are unknown".14

The WADA Prohibited List 2026 places fonturacetam, written "4-phenylpiracetam (carphedon)", under S6 stimulants, in the non-specified group S6.A, in a class headed "PROHIBITED IN-COMPETITION".1 The app's note also says it is banned by WADA. Jędrejko and colleagues (Drug Testing and Analysis, 2023) write that "The first nootropic prohibited in sport was fonturacetam (4-phenylpiracetam, carphedon) in 1998".12 Three of that review's authors are affiliated with Banned Substances Control Group, Los Angeles; the PubMed record gives no funding statement.12 Kim and colleagues at the Korea Institute of Science and Technology (Analyst, 1999) described a urine method for carphedon with a limit of detection of 0.01 microgram per mL, which "can be applied to doping analysis for stimulants".13 The app's note lists it as unscheduled in the United States and as prescription in Russia and the EU. Cohen and colleagues (Neurology: Clinical Practice, 2021) searched two supplement databases for products labeled as containing omberacetam, aniracetam, phenylpiracetam or oxiracetam, "4 drugs not approved for human use in the United States".14 Of 10 products analyzed, "phenylpiracetam and oxiracetam, were listed on product labels but not detected in the products".14 The authors list limitations including "We tested only supplements labeled as containing 1 of the 4 piracetam analogs in 2 databases at one point in time" and "Our results are not generalizable to all dietary supplements labeled as containing a piracetam analog", and report "No targeted funding reported"; the disclosures state that one author also coordinates a conference that receives support from supplement-related companies.14 Vanhee and colleagues (Journal of Xenobiotics, 2025), reporting for official medicines control laboratories in Europe and Australia, documented "159 samples containing 34 distinct molecules".11 Phenylpiracetam appears in their table once, as a sample classed "SF medicine" (substandard and falsified), described as "not authorised for human use by any health authority in the EU or Australia".11 They also write that "bulk quantities of raw material were intercepted with purities close to 100%", and call phenylpiracetam "available as a prescription medication in Russia".11 The authors write that their findings "likely represent only a small fraction of this expanding market", and state "This research received no external funding".11 The app's note says it is a prescription drug in the EU; Vanhee and colleagues state it is not authorised by any EU health authority.11

8

What is not known

The PubMed and ClinicalTrials.gov searches described above identified no human half-life, bioavailability or time-to-peak figure for phenylpiracetam, so the app's figures have no figure from the sources beside them. The human efficacy reports read are from asthenia and mood settings in Russian-language journals, and their PubMed records give no funding, limitations or adverse event counts for the largest observational program. The only registered trial identified, NCT07852130, lists no posted results in the record read. Findings on the dopamine transporter, body weight and inflammation come from mice and rats, and the searches did not identify a human study of them. Whether tolerance builds, and whether pairing with choline changes headaches, are statements in the app's note that the records read neither support nor contradict. The longest human treatment period in the records read is three months in an observational program, and six months in the registered entry without results.

What is phenylpiracetam?

Phenylpiracetam is a racetam also called fonturacetam or carphedon and sold under the name Phenotropil.1,2 Malykh and Sadaie describe it as "more potent than piracetam" without giving a multiple in the PubMed record.3

What is the half-life of phenylpiracetam?

The app lists a half-life of about 4 hours. The sources read give no human half-life figure to set beside it.

Is phenylpiracetam banned by WADA?

Yes, the WADA Prohibited List 2026 lists fonturacetam (4-phenylpiracetam, carphedon) under S6.A non-specified stimulants.1 The class is headed "PROHIBITED IN-COMPETITION".1

Is phenylpiracetam approved by the FDA?

No label for phenylpiracetam was identified in DailyMed (0 labels). Cohen and colleagues describe phenylpiracetam as one of "4 drugs not approved for human use in the United States".14

Is phenylpiracetam a prescription drug in Russia?

Vanhee and colleagues write that phenylpiracetam "is available as a prescription medication in Russia".11 They add that it is "not authorised for human use by any health authority in the EU or Australia".11

What did the studies find in asthenia?

A meta-analysis of 11 articles and 549 patients reported an average MFI-20 reduction of 16.3 points (95% CI 8.85-23.85) after a one-month course of fonturacetam at 200 mg daily.8 The PubMed record does not say whether the change was measured against a control group.8 The same record reports that the frequency of side effects averaged 5.5% and that side effects were transient and completely regressed within a week of continued treatment.8

Does phenylpiracetam act on dopamine?

In mouse radioligand binding assays, "DAT was the only significant molecular target found for R-PhP".6 That finding is from mice and concerns the R-enantiomer, not from people.6

Do supplements labeled as containing phenylpiracetam contain it?

In one US test of 10 products, phenylpiracetam was "listed on product labels but not detected in the products".14 The authors state that their results are "not generalizable to all dietary supplements labeled as containing a piracetam analog".14

Can phenylpiracetam be detected in urine?

A 1999 method paper by Kim and colleagues reported detecting carphedon in human urine with a limit of detection of 0.01 microgram per mL.13

11

References

  1. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  2. Zvejniece L, et al. Investigation into stereoselective pharmacological activity of phenotropil. Basic Clin Pharmacol Toxicol 2011. PMID 21689376
  3. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs 2010. PMID 20166767
  4. Gromova OA, Torshin IY. Pharmacological effects of fonturacetam (Actitropil) and prospects for its clinical use. Zh Nevrol Psikhiatr Im S S Korsakova 2024. PMID 39269293
  5. Zvejniece L, et al. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity. Pharmacol Biochem Behav 2017. PMID 28743458
  6. Zvejniece L, et al. Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. Inflammopharmacology 2020. PMID 32279140
  7. Fedin AI, et al. Treatment of asthenic syndrome in patients with chronic brain ischemia: results of the non-interventional observational program TRIUMPH. Zh Nevrol Psikhiatr Im S S Korsakova 2014. PMID 25726789
  8. Devlikamova FI, Safina DR. Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. Zh Nevrol Psikhiatr Im S S Korsakova 2025. PMID 40047835
  9. Medvedev VE, et al. New possibilities of pharmacotherapy in cardiovascular patients with mental disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2014. PMID 25403298
  10. Gouda AM. Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity. ClinicalTrials.gov NCT07852130, 2026. NCT07852130
  11. Vanhee C, et al. The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. J Xenobiot 2025. PMC12193813
  12. Jędrejko K, et al. Unauthorized ingredients in "nootropic" dietary supplements: a review of the history, pharmacology, prevalence, international regulations, and potential as doping agents. Drug Test Anal 2023. PMID 37357012
  13. Kim S, et al. Determination of carphedon in human urine by solid-phase microextraction using capillary gas chromatography with nitrogen-phosphorus detection. Analyst 1999. PMID 10746314
  14. Cohen PA, et al. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Neurol Clin Pract 2021. PMC8382366